Nation
World
Politics
Sports
Business
Entertainment
Life
Tech
Science
Opinion
Crime
Health
Oddities

Experts say FDA needs more regulatory flexibility

Por: The Hill Health March 01, 2023

thumbnail

Strict regulations on drug safety and testing make it difficult to develop new treatments for rare, obscure and deadly diseases, according to experts. As the Orphan Drug Act turns 40, advocates want Congress and the Food and Drug Administration (FDA) to be more flexible when supporting the development of treatments and cures for rare diseases.  “Quality and access are the two largest challenges for the next few years,” Thomas Crawford, a... + full article



Similar News

House Dems raise issues with ‘atypical’ FDA review process for Alzheimer’s drug

Politico USA Health December 30, 2022

thumbnailThe FDA’s collaboration with Biogen, the maker of a controversial Alzheimer’s drug, before it granted the product accelerated approval was “atypical” and ran afoul of the agency’s protocol for documenting interactions with drug companies, according to a joint House... + más

Alzheimer's drug approval by FDA 'rife with irregularities,' probe finds | Los Angeles Times

Probe: Alzheimer's drug approval 'rife with irregularities' | ABC News


Panel warns FDA’s beleaguered tobacco unit lacks direction

ABC News USA Health December 20, 2022

thumbnailWASHINGTON -- The lack of clear direction and priorities at the U.S. Food and Drug Administration's tobacco division has hampered its ability to regulate electronic cigarettes and other products, according to an expert panel assembled to examine problems at the agency.A... + más

Panel warns FDA’s beleaguered tobacco unit lacks direction | Associated Press

Panel warns FDA’s beleaguered tobacco unit lacks direction | WPLG Local 10


Panel warns FDA’s beleaguered tobacco unit lacks direction

WPLG Local 10 USA Politics December 20, 2022

thumbnailWASHINGTON – The lack of clear direction and priorities at the U.S. Food and Drug Administration's tobacco division has hampered its ability to regulate electronic cigarettes and other products, according to an expert panel assembled to examine problems at the agency.A... + más

Panel warns FDA’s beleaguered tobacco unit lacks direction | ABC News

Panel warns FDA’s beleaguered tobacco unit lacks direction | Associated Press


Panel warns FDA’s beleaguered tobacco unit lacks direction

Associated Press USA Politics December 19, 2022

thumbnailWASHINGTON (AP) — The lack of clear direction and priorities at the U.S. Food and Drug Administration’s tobacco division has hampered its ability to regulate electronic cigarettes and other products, according to an expert panel assembled to examine problems at the agency.A... + más

Panel warns FDA’s beleaguered tobacco unit lacks direction | ABC News

Panel warns FDA’s beleaguered tobacco unit lacks direction | WPLG Local 10


ALS drug wins FDA approval despite questionable data

ABC News USA Health September 30, 2022

thumbnailWASHINGTON -- A much-debated drug for Lou Gehrig’s disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.Amylyx Pharmaceuticals said the Food and... + más

Highly debated Amylyx Pharmaceuticals ALS drug wins FDA approval | New York Post

ALS drug wins FDA approval despite questionable data | WPLG Local 10


ALS drug wins FDA approval despite questionable data

WPLG Local 10 USA Politics September 30, 2022

thumbnailWASHINGTON – A much-debated drug for Lou Gehrig’s disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.The Food and Drug Administration approved... + más

Highly debated Amylyx Pharmaceuticals ALS drug wins FDA approval | New York Post

ALS drug wins FDA approval despite questionable data | ABC News


ALS drug wins FDA approval despite questionable data

Associated Press USA Science September 30, 2022

thumbnailWASHINGTON (AP) — A much-debated drug for Lou Gehrig’s disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.The Food and Drug Administration... + más

Highly debated Amylyx Pharmaceuticals ALS drug wins FDA approval | New York Post

ALS drug wins FDA approval despite questionable data | ABC News



About iurex | Privacy Policy | Disclaimer |